ArticleGut and liver2010
Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report.
Article in Gut and liver, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2012Trial
- Regorafenib Induced Interstitial Pneumonia in a Patient With Refractory Rectal Cancer.Respirology case reports · 2025Article
- Regorafenib pulmonary toxicity: A case of cavitary lung disease and ARDS treated with infliximab.Respiratory medicine case reports · 2025Article
- Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma.Internal medicine (Tokyo, Japan) · 2022Article
- Review
- Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.Clinical journal of gastroenterology · 2019Article
- Article
- Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.Nature reviews. Clinical oncology · 2016Review
- Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: An autopsy case report.Oncology letters · 2015Article
- Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases.Clinical journal of gastroenterology · 2012Article
- Pulmonary toxicities from targeted therapies: a review.Targeted oncology · 2011Review
- Interstitial Lung Disease Induced by Pazopanib Treatment.Internal medicine (Tokyo, Japan)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sorafenib is an oral multikinase inhibitor that has shown a survival benefit in patients with advanced hepatocellular carcinoma, and is considered to be generally safe. We treated a patient with interstitial lung disease that was associated with sorafenib therapy for the treatment of advanced hepatocellular carcinoma. A 74-year-old man with hepatitis-C-virus-related hepatocellular carcinoma was treated with sorafenib. After 8 days of sorafenib administration, he received radiation therapy for an intrahepatic tumor located in segment eight. On the 24th day of sorafenib treatment, the patient developed acute interstitial pneumonitis that rapidly improved after the discontinuation of sorafenib and treatment with high-dose steroids. This case alerts physicians to the possibility of sorafenib-induced interstitial lung disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.